Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013
06 sept. 2013 16h01 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Sept. 6, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Therapeutics Reports Second Quarter 2013 Financial Results
06 août 2013 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius to Present at the JMP Securities Healthcare Conference
08 juil. 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, July 8, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Therapeutics Announces Publication of Antibiotic Safety Study in Antimicrobial Agents and Chemotherapy
12 juin 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, June 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious...
Trius Appoints Matthew Onaitis as General Counsel
03 juin 2013 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, June 3, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin
13 mai 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, May 13, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Therapeutics Reports First Quarter 2013 Financial Results
07 mai 2013 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, May 7, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for...
Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting
29 avr. 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO and BERLIN, April 29, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of antibiotics for serious...
Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting
23 avr. 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of a large, late-stage human study, called ESTABLISH 2, and multiple other...
Trius Appoints Seth Fischer to Its Board of Directors
03 avr. 2013 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, April 3, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the appointment of Seth H. Z. Fischer to its Board of Directors. Mr. Fischer was the former Company...